Effient Shown to Lower Mortality Rates in CABG Patients
November 16, 2010—Daiichi Sankyo Company, Ltd. (Tokyo, Japan) and Eli Lilly and Company (Indianapolis, IN) announced that new results from an observational substudy from TRITON-TIMI 38 showed that patients treated with the companies' Effient (prasugrel) before coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, New York, NY) (2.3% vs 8.7%, respectively; P = .016).
